Formulary Decisions
Search for the outcome of decisions made by the Formulary Committee
Pembrolizumab
Keytruda
Not routinely available
SMC (SMC2915)
18/03/2026
Indication
In combination with pemetrexed and platinum chemotherapy for the first‑line treatment of adults with unresectable non-epithelioid malignant pleural mesothelioma.
Therapeutic Area
Malignant disease and immunosuppression
Status Description
Not routinely available as not recommended for use in NHSScotland
Formulation
Concentrate for solution for infusion
Comments
Link to Advice
Advice Published
09/03/2026
SMC Submission Type
Non submission
SMC Status
Not recommended